In a randomized controlled trial, 190 NASH patients with moderate or severe fibrosis received subcutaneous injections of tirzepatide, at 5 mg, 10 mg, or 15 mg, or placebo weekly for 52 weeks
Recent clinical data indicates that tirzepatide, a dual-action peptide medication, may help reduce liver fat accumulation and improve liver function markers in people with obesity and metabolic dysfunction
Sara Hassan, Email: [email protected]
The mitochondria may be the powerhouse of the cell, but mounting evidence suggests this organelle is also a driving force behind cancer
The FDA says people may be subject to dosing errors
Support for Overall Well-being Elevated growth hormone levels contribute to better sleep quality, increased energy, and improved skin health